Actualites therapeutiques 2000.

Scheen, André

No full text

Article (Scientific journals)

Actualites therapeutiques 2000.

Scheen, André

2000 • In Revue Médicale de Liège, 55 (9), p. 852-61

Peer reviewed

Permalink
https://hdl.handle.net/2268/12251

PubMed
11105601

Files (0)Send to Details Statistics Bibliography Similar publications

Files

Full Text

No document available.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Anti-Infective Agents/therapeutic use; Antihypertensive Agents/therapeutic use; Antilipemic Agents/therapeutic use; Antineoplastic Agents/therapeutic use; Antirheumatic Agents/therapeutic use; Belgium; Central Nervous System Agents/therapeutic use; Drug Therapy/classification; Gastrointestinal Agents/therapeutic use; Humans; Hypertension/drug therapy; Hypoglycemic Agents/therapeutic use; Immunosuppressive Agents/therapeutic use; Platelet Aggregation Inhibitors/therapeutic use; Respiratory System Agents/therapeutic use

Abstract :

[en] The most important drugs registered and/or launched in Belgium during the last year in the various disciplines of internal medicine will be briefly described. The originality of each molecule as well as its modalities of appropriate use in clinical practice will be emphasized.

Disciplines :

Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Actualites therapeutiques 2000.

Alternative titles :

[fr] Current therapeutics 2000

Publication date :

2000

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Hopital de Baviere, Liège, Belgium

Volume :

Issue :

Pages :

852-61

Peer reviewed :

Peer reviewed

Available on ORBi :

since 06 May 2009

Statistics

Number of views

43 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Scheen A.J. (1998) Actualites therapeutiques 1997-1998 (Premiere partie). Rev Med Liege 53:459-466.
Scheen A.J. (1999) Actualites therapeutiques 1999. Rev Med Liege 54:725-734.
Kulbertus H. (2000) Le medicament du mois. Le telmisartan (Micardis(®)). Rev Med Liege 55:57-60.
Krzesinski J.M. (1999) Le medicament du mois. La lercanidipine (Zanidip(®)). Rev Med Liege 54:832-834.
Scheen A.J. (2000) Le medicament du mois. La moxonidine (Moxon(®)). Rev Med Liege 55:61-63.
Awtry E.H., Loscalzo J. (2000) Aspirin. Circulation 101:1206-1218.
Schafer A.I. (1996) Antiplatelet therapy. Am J Med 101:199-209.
Hervey P.S., Goa K.L. (1999) Extended-release dipyridamole/aspirin. Drugs 58:469-475.
Herbert J.M., Savi P. (1999) Biochemical and pharmacological properties of clopidogrel: A new ADP-receptor antagonist. Eur Heart J (SUPPL. A).
(1996) A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348:1329-1339.
(1998) Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. New Engl J Med 338:1488-1497.
(1999) Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 96:1445-1453.
Foster R.H., Wiseman L.R. (1998) Abciximab. An updated review of its use in ischaemic heart disease. Drugs 56:629-665.
Bartsch P. (2000) Traitement de l'asthme et recommandations internationales. Rev Med Liege 55:325-331.
Scheen A.J. (1998) Le medicament du mois. Le formoterol (Oxis(®) Turbohaler(TM)). Rev Med Liege 53:715-718.
Jarvis B., Faulds D. (1999) Lamivudine. A review of its therapeutic potential in chronic hepatitis B. Drugs 58:101-141.
Sadzot B. (2000) Le medicament, du mois. Le topiramate (Topamax(®)). Rev Med Liege 55:114-116.
Tomson T., Stefan H. (1999) Gabitril: Current aspects, future perspectives. Epilepsia 40(SUPPL. 9).
Sim A. (1999) Rivastigmine: A review. Hosp Med 60:731-735.
Nkoghe D., Scheen A.J. (2000) La grippe: De la prevention vaccinale au traitement antiviral. Rev Med Liege 55:19-23.
Nkoghe D., Leonard P., Moutschen M., Demonty J. (1999) Le medicament du mois. La nevirapine (Viramune(®)). Rev Med Liege 54:948-951.
Nkoghe D., Moutschen M., Demonty J. (2000) Recommandations pour la prise en charge du patient infecte par le VIH. I. L'adolescent et l'adulte. Rev Med Liege 55:417-423.
Vigouroux C., Gharakhanian S., Salhi Y. (1999) Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diab Metab 25:383-392.
Scheen A.J. (2000) Le medicament du mois. Le glimepiride (Amarylle(®)). Rev Med Liege 55:184-186.
Scheen A.J., Paquot N. (1999) Le diabete de type 2: Approches diagnostiques, objectifs glycemiques et strategies therapeutiques. Rev Med Liege 54:659-666.
Scheen A.J., Lefebvre P.J. (1999) Troglitazone: Antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 22:1568-1577.
Scheen A.J. (2000) Le medicament du mois. La cerivastatine (Lipobay(®), Cholstat(®)). Rev Med Liege 55:117-120.
Scheen A.J. (2000) Le medicament du mois. Le rofecoxib (Vioxx(®)). Rev Med Liege 55:751-753.
Mitlak B.H., Cohen F.J. (1999) Selective estrogen receptors modulators. A look ahead. Drugs 57:653-663.
Delmas P.D., Bjarnason N.H., Mitlak B.H. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.
Kaufman J.M., Body J.J., Boonen S. (2000) L'osteoporose involutive de la femme: Strategie therapeutique. Le point de vue actualise du Belgian Bone Club. Rev Med Liege 55:443-448.
Foidart J.M., Desreux J., Pintiaux A. (2000) Les traitements post-menopause. A revoir? Une polemique nouvelle !. Rev Med Liege 55:156-160.
Cummings S.R., Eckert S., Krueger K.A. (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 281:2189-2197.
Wiseman L.R., Adkins J.C., Plosker G.L., Goa K.L. (1999) Oxaliplatin. A review of its use in the management of metastatic colorectal cancer. Drugs and Aging 14:459-475.
Creemers G.J., Lund B., Verweij J. (1994) Topoisomerase I inhibitor: Topotecan and irinotecan. Cancer Treat Rev 20:73-96.
Douillard J.Y., Cunningahm D., Roth A.D. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastaic colorectal cancer: A multicentre randomised trial. Lancet 355:1041-1047.
Zalcberg J.R., Cunningham D., Van Custem E. (1996) ZD1694: A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 14:716-721.
Gast P., Bours V., Detrooz B., Colette M.Y., Booz V. (2000) Recommandations en matiere de traitement du cancer rectal. Rev Med Liege 55:350-355.
Jerusalem G., Bours V., Fillet G. (2000) Traitement adjuvant du cancer du sein: Meta-analyse et recommandations therapeutiques. Rev Med Liege 55:356-359.
Lonning P.E. (2000) Is there a growing role for endocrine therapy in the treatment of breast cancer?. Drugs 60:11-21.
Masamura S., Adlercreutz H., Harvey H. (1994) Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 33:19-26.
Scheen A.J. (1998) Actualites therapeutiques 1997-1998 (Seconde partie). Rev Med Liege 53:518-523.
Billaud E.M. (2000) Clinical pharmacology of immunosuppressive drugs: Year 2000 - Time for alternatives. Therapie 55:177-183.
Vincenti F. (1999) Potential of daclizumab in solid organ transplantation. BioDrugs 11:333-341.
Onrust S.V., Wiseman L.R. (1999) Basiliximab. Drugs 57:207-213.
Scheen A.J. (2000) Insulino-independance prolongee apres transplantation d'ilots de Langerhans chez le patient diabetique de type 1: L'aboutissement d'un reve?. Rev Med Liege 55:803-805.